Empagliflozin in Patients with Chronic Kidney Disease
Source : https://www.nejm.org/doi/10.1056/NEJMoa2204233
Our apologies. An error occurred while setting your user cookie. Please set your browser to accept cookies to continue. NEJM.org uses cookies to improve performance by remembering your session ID...
Conclusions: Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo.
Share
Impact of empagliflozin on left atrial mechanical and conduction functions in patients with type 2 diabetes mellitus - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36308321/
doi: 10.1002/jcu.23384. Online ahead of print. 1 Faculty of Medicine, Department of Cardiology, Siirt University, Siirt, Turkey. 2 Faculty of Medicine, Department of Cardiology, Altinbas University, Istanbul, Turkey. 3 Faculty...
Conclusion: Empagliflozin may enhance the structure and electrical conductions of the atrium and may prevent DM patients from DM-2-related functional disorder and arrhythmia.
Share
Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36297433/
Despite the reduction of cardiovascular events, including the risk of death, associated with sodium/glucose cotransporter 2 inhibitors (SGLT2i), their basic action remains unclear. Sodium/hydrogen exchanger (NHE) has been proposed as...
Conclusion/Relevance: We described upregulation in NHE11 and NHE1, but only NHE11 correlated with human cardiac dysfunction, and its levels were reduced after treatment with empagliflozin. These results propose NHE11 as a potential target of SGLT2i in cardiac tissue.
Share
Physicians' Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36294370/
1 Division of Endocrinology, Diabetes & Metabolic Diseases, Sidney Kimmel Medical College, Thomas Jefferson University, 211 S Ninth Street, Suite 600, Philadelphia, PA 19107, USA. 2 INOVA Heart and Vascular...
Conclusion: Recognition by physicians that the benefits of SGLT-2i use on clinical outcomes outweigh the risks will result in the integration of SGLT-2is into clinical practice and lead to improved patient care and outcomes.
Share
The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial - Clinical Research in Cardiology
Source : https://link.springer.com/article/10.1007/s00392-022-02119-7
Introduction Sodium-glucose co-transporter 2 (SGLT2) inhibitors have cardiovascular protective properties in addition to the metabolic effects and represent a cornerstone of treating patients with chronic heart failure (CHF). We hypothesised...
Conclusion: This trial showed a significant decrease in skin sodium content after 1 and 3 months of treatment with empagliflozin. The decrease in skin sodium content may reflect a decrease in subclinical micro-oedema or/and in non-osmotic bound tissue sodium, both reported to impair left ventricular function.
Share